MNOV MEDICINOVA INC

Nasdaq medicinova.com


$ 1.46 $ -0.04 (-3 %)    

Wednesday, 05-Nov-2025 12:54:10 EST
QQQ $ 625.42 $ 6.95 (1.12 %)
DIA $ 473.80 $ 2.88 (0.61 %)
SPY $ 680.45 $ 5.41 (0.8 %)
TLT $ 89.03 $ -0.48 (-0.54 %)
GLD $ 366.49 $ 0.04 (0.01 %)
$ 1.42
$ 1.53
$ 1.46 x 13
$ 1.50 x 21
$ 1.43 - $ 1.55
$ 1.13 - $ 2.55
561,298
na
69.65M
$ 0.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-15-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 02-16-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 02-16-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 02-19-2021 12-31-2020 10-K
20 10-26-2020 09-30-2020 10-Q
21 07-28-2020 06-30-2020 10-Q
22 04-23-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-K
24 10-25-2019 09-30-2019 10-Q
25 07-25-2019 06-30-2019 10-Q
26 04-25-2019 03-31-2019 10-Q
27 02-13-2019 12-31-2018 10-K
28 10-25-2018 09-30-2018 10-Q
29 07-23-2018 06-30-2018 10-Q
30 04-25-2018 03-31-2018 10-Q
31 02-13-2018 12-31-2017 10-K
32 10-23-2017 09-30-2017 10-Q
33 07-26-2017 06-30-2017 10-Q
34 04-26-2017 03-31-2017 10-Q
35 02-14-2017 12-31-2016 10-K
36 10-25-2016 09-30-2016 10-Q
37 07-26-2016 06-30-2016 10-Q
38 04-27-2016 03-31-2016 10-Q
39 02-25-2016 12-31-2015 10-K
40 10-29-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-medicinova-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.

 medicinova-completes-patient-enrollment-in-its-phase-2-mn-001-natg-202-trial-of-mn-001-tipelukast-for-hypertriglyceridemia-and-non-alcoholic-fatty-liver-disease-due-to-type-2-diabetes-top-line-data-are-expected-by-the-summer-of-2026

The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001(tipelukast)....

 d-boral-capital-maintains-buy-on-medicinova-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.

 why-did-medicinova-stock-mnov-jump-over-87-in-after-hours-trading

MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research.

 d-boral-capital-maintains-buy-on-medicinova-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.

 medicinova-completes-patient-enrollment-in-phase-23-clinical-trial-combat-als-for-treatment-of-amyotrophic-lateral-sclerosis

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the T...

 medicinova-issues-shareholder-update-secures-30m-sepa-to-advance-rd-as-combat-als-trial-hits-enrollment-target-nih-funded-eap-and-mn-001-diabetes-study-near-completion

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the T...

 medicinova-files-prospectus-relates-to-offer-sale-of-up-to-25m-shares-of-common-stock-by-ya-ii-pn-ltd

-SEC Filing

 medicinova-q2-eps-007-beats-010-estimate-sales-134599k

MediciNova (NASDAQ:MNOV) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by...

 d-boral-capital-maintains-buy-on-medicinova-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.

 b-riley-securities-maintains-buy-on-medicinova-lowers-price-target-to-5

B. Riley Securities analyst Mayank Mamtani maintains MediciNova (NASDAQ:MNOV) with a Buy and lowers the price target from $6...

 medicinova-q1-eps-006-beats-014-estimate

MediciNova (NASDAQ:MNOV) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14) by...

 d-boral-capital-maintains-buy-on-medicinova-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION